Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03294616 · ClinicalTrials.gov registry record · NA

Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

A NA study of Gastroparesis and Scleroderma, sponsored by Johns Hopkins University.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT03294616: Completed NA study of Gastroparesis and Scleroderma, sponsored by Johns Hopkins University.

NCT03294616 is a NA study of Gastroparesis and Scleroderma that has completed, run by Johns Hopkins University. The registered enrollment target is 23 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03294616, a NA study of Gastroparesis and Scleroderma, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed. Weak electrical current will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions. The stimulator can be attached to the skin near the acupuncture points and therefore daily activity of the patient does not need to be altered. Two experiments are designed to prove the feasibility of the proposed therapy for gastric complications of Scleroderma .

Primary Outcome

On the first visit; The validated UCLA SCTC GIT2.0 ("University of California at Los Angeles Scleroderma Clinical Trials Consortium Gastro-Intestinal Tract Instrument version 2.0") for SSc will be the primary outcome measurement; it includes 7 categories: reflux, distention and bloating, fecal soilage, diarrhea, social functioning, emotional well-being and constipation

Interventions

  • DEVICE transcutaneous electroacupuncture

Study Locations (1)

Maryland

  • Johns Hopkins Bayview Medical Center - Baltimore

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2017-02-06
Est. Completion 2019-11-20
Phase NA
Johns Hopkins University

1,448 total trials

What the finished NCT03294616 record still lists

NCT03294616 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (92% lower).

The record links to 2 conditions, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which transcutaneous electroacupuncture is the first listed.

NCT03294616 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT03294616 about?

NCT03294616 is a clinical study titled "Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma". An innovative method of needleless transcutaneous electroacupuncture (TEA) using a newly developed watch-size stimulator is proposed. Weak electrical current will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions. The stimulator can be attached to t...

What is the current status of trial NCT03294616?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2017-02-06. Estimated completion is 2019-11-20.

What conditions does trial NCT03294616 study?

This clinical trial studies the following conditions: Gastroparesis, Scleroderma.

What interventions are being tested in trial NCT03294616?

The interventions under investigation include: transcutaneous electroacupuncture (DEVICE).

Who is sponsoring clinical trial NCT03294616?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03294616 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03294616's enrollment target sits among peer trials

23 33rd of 44 higher than 12 of 44 other Gastroparesis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03294616, the US trial registry maintained by the National Library of Medicine. NCT03294616 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.